Difference between revisions of "Team:British Columbia/Imidacloprid"
| Line 62: | Line 62: | ||
} | } | ||
</style><table class="tableizer-table"> | </style><table class="tableizer-table"> | ||
| − | <tr class="tableizer-firstrow"><th> | + | <tr class="tableizer-firstrow"><th>iGEM Part Number</th><th>Type</th><th>Description</th><th>LacI Repressor</th><th>pelB</th></tr> |
| − | + | ||
<tr><td>BBa_K1813003</td><td>Coding</td><td>CYP6CM1</td><td>No</td><td>No</td></tr> | <tr><td>BBa_K1813003</td><td>Coding</td><td>CYP6CM1</td><td>No</td><td>No</td></tr> | ||
<tr><td>BBa_K1813004</td><td>Coding</td><td>CYP6G1</td><td>No</td><td>No</td></tr> | <tr><td>BBa_K1813004</td><td>Coding</td><td>CYP6G1</td><td>No</td><td>No</td></tr> | ||
| Line 76: | Line 75: | ||
<tr><td>BBa_K1813027</td><td>Composite</td><td>LacI Reversed CPY6CM1</td><td>Yes</td><td>No</td></tr> | <tr><td>BBa_K1813027</td><td>Composite</td><td>LacI Reversed CPY6CM1</td><td>Yes</td><td>No</td></tr> | ||
<tr><td>BBa_K1813028</td><td>Composite</td><td>LacI Reversed AgamNADPH Reductase</td><td>Yes</td><td>No</td></tr> | <tr><td>BBa_K1813028</td><td>Composite</td><td>LacI Reversed AgamNADPH Reductase</td><td>Yes</td><td>No</td></tr> | ||
| − | <tr><td>BBa_K1813032</td><td>Composite</td><td>LacIR AgCPR | + | <tr><td>BBa_K1813032</td><td>Composite</td><td>LacIR AgCPR CYP2D6</td><td>Yes</td><td>No</td></tr> |
<tr><td>BBa_K1813033</td><td>Composite</td><td>LacIR AgCPR CYP6G1</td><td>Yes</td><td>No</td></tr> | <tr><td>BBa_K1813033</td><td>Composite</td><td>LacIR AgCPR CYP6G1</td><td>Yes</td><td>No</td></tr> | ||
<tr><td>BBa_K1813034</td><td>Composite</td><td>LacIR AgCPR CYP6CM1</td><td>Yes</td><td>No</td></tr> | <tr><td>BBa_K1813034</td><td>Composite</td><td>LacIR AgCPR CYP6CM1</td><td>Yes</td><td>No</td></tr> | ||
| Line 85: | Line 84: | ||
<tr><td>BBa_K1813053</td><td>Coding</td><td>pelB AgCPR</td><td>No</td><td>Yes</td></tr> | <tr><td>BBa_K1813053</td><td>Coding</td><td>pelB AgCPR</td><td>No</td><td>Yes</td></tr> | ||
<tr><td>BBa_K1813054</td><td>Composite</td><td>ptac pelB AgCPR</td><td>No</td><td>Yes</td></tr> | <tr><td>BBa_K1813054</td><td>Composite</td><td>ptac pelB AgCPR</td><td>No</td><td>Yes</td></tr> | ||
| − | <tr><td>BBa_K1813055</td><td>Coding</td><td>pelB | + | <tr><td>BBa_K1813055</td><td>Coding</td><td>pelB CYP2D6</td><td>No</td><td>Yes</td></tr> |
| − | <tr><td>BBa_K1813056</td><td>Composite</td><td>ptac pelB | + | <tr><td>BBa_K1813056</td><td>Composite</td><td>ptac pelB CYP2D6</td><td>No</td><td>Yes</td></tr> |
<tr><td>BBa_K1813057</td><td>Composite</td><td>LacIR pelB CYP6G1</td><td>Yes</td><td>Yes</td></tr> | <tr><td>BBa_K1813057</td><td>Composite</td><td>LacIR pelB CYP6G1</td><td>Yes</td><td>Yes</td></tr> | ||
<tr><td>BBa_K1813058</td><td>Composite</td><td>LacIR pelB CYP6CM1</td><td>Yes</td><td>Yes</td></tr> | <tr><td>BBa_K1813058</td><td>Composite</td><td>LacIR pelB CYP6CM1</td><td>Yes</td><td>Yes</td></tr> | ||
<tr><td>BBa_K1813059</td><td>Composite</td><td>LacIR pelB AgCPR</td><td>Yes</td><td>Yes</td></tr> | <tr><td>BBa_K1813059</td><td>Composite</td><td>LacIR pelB AgCPR</td><td>Yes</td><td>Yes</td></tr> | ||
| − | <tr><td>BBa_K1813060</td><td>Composite</td><td>LacIR pelB | + | <tr><td>BBa_K1813060</td><td>Composite</td><td>LacIR pelB CYP2D6</td><td>Yes</td><td>Yes</td></tr> |
<tr><td>BBa_K1813061</td><td>Composite</td><td>ptac pelB AgCPR pelb CYP6G1</td><td>No</td><td>Yes</td></tr> | <tr><td>BBa_K1813061</td><td>Composite</td><td>ptac pelB AgCPR pelb CYP6G1</td><td>No</td><td>Yes</td></tr> | ||
<tr><td>BBa_K1813062</td><td>Composite</td><td>ptac pelB AgCPR pelb CYP6CM1</td><td>No</td><td>Yes</td></tr> | <tr><td>BBa_K1813062</td><td>Composite</td><td>ptac pelB AgCPR pelb CYP6CM1</td><td>No</td><td>Yes</td></tr> | ||
| − | <tr><td>BBa_K1813063</td><td>Composite</td><td>ptac pelB AgCPR pelb | + | <tr><td>BBa_K1813063</td><td>Composite</td><td>ptac pelB AgCPR pelb CYP2D6</td><td>No</td><td>Yes</td></tr> |
<tr><td>BBa_K1813064</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB-CYP6G1</td><td>Yes</td><td>Yes</td></tr> | <tr><td>BBa_K1813064</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB-CYP6G1</td><td>Yes</td><td>Yes</td></tr> | ||
<tr><td>BBa_K1813065</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB CYP6CM1</td><td>Yes</td><td>Yes</td></tr> | <tr><td>BBa_K1813065</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB CYP6CM1</td><td>Yes</td><td>Yes</td></tr> | ||
| − | <tr><td>BBa_K1813066</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB | + | <tr><td>BBa_K1813066</td><td>Composite</td><td>LacIR pelB AgCPR ptac pelB CYP2D6</td><td>Yes</td><td>Yes</td></tr> |
</table> | </table> | ||
</p> | </p> | ||
Revision as of 22:51, 18 September 2015
Degradation of
Imidacloprid
Imidacloprid is a neonicotinoid commonly used in pesticides around the world [1]. Studies have shown that the use of this pesticide has adverse effects on insects since it acts as an neurotoxin by binding and blocking the nicotinergic neuronal pathway [2]. As a result, honeybees become paralyzed and eventually die [3]. Studies have shown that there are three cytochrome P450s (CYPs) capable of modifying imidacloprid into less toxic substances [4-6]. In light of such findings, experiments were conducted in order to demonstrate that CYP6G1, CYP2D6, and CYP6CM1 could modify imidacloprid into less toxic compounds. In order to test for such modifications, constructs were created to code for: 1) a cytochrome P450 (CYP), 2) a targeting signal sequence, pelB, and 3) an NADPH-cytochrome P450 oxidoreductase (CPR).
In an attempt to improve CYP expression, pelB was added to the constructs. pelB targets the CYPs to the periplasm of the cell, where the CYPs are fully functional [7]. In addition, a P450 oxidoreductase (CPR) is also required to make the CYPs fully functional. AgCPR, a P450 oxidoreductase from Anopheles gambiae, reduces the CYPs by transferring two electrons from NADPH, a reaction necessary for the hydroxylation of imidacloprid by the CYPs [8]. As such, AgCPR was included in the constructs.
Final constructs were inserted into E. coli and tests were conducted to test the expression of the CYPs in E. coli as well as to test the degradative ability of the CYPs on imidacloprid. Two methods were used in the construction of the final constructs: 1) megaprimer mutagenesis PCR to insert pelB and 2) standard assembly to assemble the CYPs and the AgCPR. Gene expression was tested via SDS-PAGE electrophoresis and imidacloprid metabolism assays were conducted using HPLC.
Goals
Three cytochrome P450s, CYP6CM1, CYP6G1 and CYP2D6, have been found to modify imidacloprid (IMI) into less toxic compounds, primarily 4- and 5-hydroxyimidacloprid. Our project goals were to:
Construct Development
All constructs were made using restriction digest and ligation methods (standard assembly). pelB was inserted upstream of the CYPs and the AgCPR using megaprimer mutagenesis PCR. Please refer to “Complete Construct Table” for all construct designs. Refer to “Restriction Digest Protocol” for standard assembly methods. Further, refer to the “Mutagenesis PCR” protocol used to insert pelB upstream of the CYPs and the AgCPR.
| iGEM Part Number | Type | Description | LacI Repressor | pelB |
|---|---|---|---|---|
| BBa_K1813003 | Coding | CYP6CM1 | No | No |
| BBa_K1813004 | Coding | CYP6G1 | No | No |
| BBa_K1813005 | Coding | HUMCYPDB1 | No | No |
| BBa_K1813010 | Coding | A. gamb NADPH Reductase | No | No |
| BBa_K1813011 | Composite | ptac CYP6CM1 term | No | No |
| BBa_K1813012 | Composite | ptac CYP6G1 term | No | No |
| BBa_K1813013 | Composite | ptac CYP2D6 term | No | No |
| BBa_K1813018 | Composite | ptac AgambNADPH term | No | No |
| BBa_K1813024 | Composite | LacI Reversed HUMCYPDB1 | Yes | No |
| BBa_K1813025 | Composite | LacI Reversed CYP6G1 | Yes | No |
| BBa_K1813027 | Composite | LacI Reversed CPY6CM1 | Yes | No |
| BBa_K1813028 | Composite | LacI Reversed AgamNADPH Reductase | Yes | No |
| BBa_K1813032 | Composite | LacIR AgCPR CYP2D6 | Yes | No |
| BBa_K1813033 | Composite | LacIR AgCPR CYP6G1 | Yes | No |
| BBa_K1813034 | Composite | LacIR AgCPR CYP6CM1 | Yes | No |
| BBa_K1813046 | Coding | pelB CYP6G1 | No | No |
| BBa_K1813050 | Composite | ptac pelB CYP6G1 | No | Yes |
| BBa_K1813051 | Coding | pelB CYP6CM1 | No | Yes |
| BBa_K1813052 | Composite | ptac pelB CYP6CM1 | No | Yes |
| BBa_K1813053 | Coding | pelB AgCPR | No | Yes |
| BBa_K1813054 | Composite | ptac pelB AgCPR | No | Yes |
| BBa_K1813055 | Coding | pelB CYP2D6 | No | Yes |
| BBa_K1813056 | Composite | ptac pelB CYP2D6 | No | Yes |
| BBa_K1813057 | Composite | LacIR pelB CYP6G1 | Yes | Yes |
| BBa_K1813058 | Composite | LacIR pelB CYP6CM1 | Yes | Yes |
| BBa_K1813059 | Composite | LacIR pelB AgCPR | Yes | Yes |
| BBa_K1813060 | Composite | LacIR pelB CYP2D6 | Yes | Yes |
| BBa_K1813061 | Composite | ptac pelB AgCPR pelb CYP6G1 | No | Yes |
| BBa_K1813062 | Composite | ptac pelB AgCPR pelb CYP6CM1 | No | Yes |
| BBa_K1813063 | Composite | ptac pelB AgCPR pelb CYP2D6 | No | Yes |
| BBa_K1813064 | Composite | LacIR pelB AgCPR ptac pelB-CYP6G1 | Yes | Yes |
| BBa_K1813065 | Composite | LacIR pelB AgCPR ptac pelB CYP6CM1 | Yes | Yes |
| BBa_K1813066 | Composite | LacIR pelB AgCPR ptac pelB CYP2D6 | Yes | Yes |
Results
Please refer to “SDS-PAGE Constructs” for SDS-PAGE results and “HPLC Constructs” for HPLC data. Refer to “SDS-PAGE Protocol” and “HPLC Protocol” for the methods used to run gene expression and metabolism assays, respectively.
Protocol Optimization
Several aspects of the SDS-PAGE and HPLC protocols could be modified in order to optimize gene expression and imidacloprid degradation. For SDS-PAGE, delta-aminolevulinic acid was added during the growth phase of the bacteria [6]. The addition of this heme precursor would “lighten” the burden of the cells by allowing for the more efficient production of heme, a cofactor required by the CYPs. In addition, overnight culture times could be extended in order to acquire more cell mass. With regards to HPLC, and in addition to the SDS-PAGE optimizations, several aspects of the HPLC protocol could be modified in order to optimize for gene expression and the degradation of imidacloprid. Such modifications would include adding more or different protease inhibitor mixes, incubating the CYP/AgCPR/imidacloprid/NADPH mixture for longer times, and incubating the mixtures with different concentrations of imidacloprid.
References
- Elbert, A., Becker, B., Hartwig, J., Erdelen, C., 1991. Imidacloprid – a new systemic insecticide. Pflanzenschutz-Nachrichten Bayer 44, 113–135
- Liu, M.Y., Casida, J.E., 1993. High affinity binding of [3 H] imidacloprid in the insect acetylcholine receptor. Pestic. Biochem. Physiol. 46, 40–46.
- Ishaaya, I. (2001). Biochemical Sites of Insecticide Action and Resistance. Springer. ISBN 3540676252.
- Joußen, N., Heckel, D.G., Haas, M., Schuphan, I., Schmidt, B., 2008. Metabolism of imidacloprid and DDT by P450 CYP6G1 expressed in cell cultures of Nicotiana tabacum suggests detoxification of these insecticides in Cyp6g1-overexpressing strains of Drosophila melanogaster, leading to resistance. Pest Manag. Sci. 64, 65–73
- Schulz-Jander, D.A., Casida, J.E., 2002. Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction. Toxicol. Lett. 132, 65–70.
- Karunker, Iris, Evangelia Morou, Dimitra Nikou, Ralf Nauen, Rotem Sertchook, Bradley J. Stevenson, Mark J.I. Paine, Shai Morin, and John Vontas. "Structural Model and Functional Characterization of the Bemisia Tabaci CYP6CM1vQ, a Cytochrome P450 Associated with High Levels of Imidacloprid Resistance." Insect Biochemistry and Molecular Biology 39.10 (2009): 697-706. Elsevier. Web.
- Pritchard, Michael P., Lesley McLaughlin, and Thomas Friedberg. "Establishment of Functional Human Cytochrome P450 Monooxygenase Systems in Escherichia Coli." Ed. Ian R. Phillips and Elizabeth A. Shephard. 320 (2006): 19-29. Springer Link. Web.
- Nikou, Dimitra, Hilary Ranson, Janet Hemingway. “An adult-specific CYP6 P450 gene is overexpressed in a pyrethroid-resistant strain of the malaria vector, Anopheles gambiae” Gene. 318 (2003): 91-102. Elsevier. Web.
UBC iGEM 2015